News 2025-02-13
Join Porton at Leading Industry Conferences to Explore Innovations and Network with Experts
Porton Pharma Solutions is thrilled to announce its participation in several major industry events across the globe during the first and second quarters of 2025. As a leading end-to-end integrated CDMO company, Porton boasts globally advanced technology platforms and extensive project delivery experience in small molecules, peptides and oligonucleotides, ADCs (including antibodies, payload-linkers, conjugation, and drug product filling), and Advanced Therapy Medicinal Products.
These events will serve as a fantastic
platform for us to showcase our latest advancements, connect with industry
leaders, and foster valuable collaborations. Come meet us!
 |
World ADC London 2025
Date: March 3- 6, 2025
Location: London, UK |
 |
The 9th Annual Frontiers in Therapeutics
and Diagnostics (FTD) Forum
Date: March 14, 2025
Location: Hilton San Diego, Del Mar, CA
|
 |
DCAT Week 2025
Date: March 17- 20, 2025
Location: New York, USA
|
 |
BIO-Europe Spring 2025
Date: March 17- 19, 2025
Location: Milan, Italy
Booth: #87
|
 |
INTERPHEX 2025
Date: April 1- 3, 2025
Location: Javits Center, NYC
|
 |
CPHI Japan
Date: April 9-11, 2025
Location: Tokyo, Japan
Booth: #5Q-18
|
 |
Swiss Biotech Day
Date: May 5- 6, 2025
Location: Congress Center Basel,
Switzerland
|
 |
2nd ADC Payload Summit
Date: May 6-8, 2025
Location: Boston, MA
|
 |
BIO Korea
Date: May 7-9, 2025
Location: Seoul, South Korea
|
|
CPHI Americas 2025
Date: May 20- 22, 2025
Location: Philadelphia, USA
Booth: #405
|
|
Chemspec Europe
Date: June 4- 5, 2025
Location: Koelnmesse, Germany
Booth: 4T29
|
|
BOS Basel 2025
Date: June 11- 12, 2025
Location: Basel, Switzerland
|
|
CPHI China
Date: June 24-26, 2025
Location: Shanghai, China
Booth: #E2A32
|
Don’t miss the opportunity to connect
with Porton at these premier events. Stay updated on the latest developments @ https://www.portonpharma.com/en/event?key=Upcoming
We look forward to seeing you there!
Others
More
News 2025-04-16
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).
News 2025-04-11
Porton Newsletter - Q1 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
